Trexquant Investment LP Cerevel Therapeutics Holdings, Inc. Transaction History

Trexquant Investment LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$20.26 - $31.91 $291,683 - $459,408	14,397 New	14,397 $314,000
Q1 2022 May 13, 2022	SELL	$23.5 - $35.38 $252,084 - $379,521	-10,727 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$29.21 - $44.64 $510,415 - $780,039	-17,474 Reduced 61.96%	10,727 $348,000
Q3 2021 Nov 12, 2021	BUY	$21.26 - $38.85 $599,553 - $1.1 Million	28,201 New	28,201 $832,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.